Stock DZ
20.04.2018 kl 12:28

Thanks snøffelen

also remember that:

Ex global VP of early clinical development at AstraZeneca is in PCI scientific advisory board (Andrew Hughes)

So together with Professor Christoph Huber, I am reassured that PCI biotech has access to both companies i.e. AstraZeneca and Astellas at a much higher level, thus the technology potential is communicated efficiently.

Should we expect a dog fight between the 2 over PCI biotech at a later stage, why not :)

Redigert 20.04.2018 kl 12:59 Arkivert